Cinclus Pharma Holding AB (publ) (STO:CINPHA)

Market Cap	786.49M +23.4%
Revenue (ttm)	57.47M +1,154.8%
Net Income	-183.97M
EPS	-3.95
Shares Out	46.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,119
Average Volume	28,630
Open	17.80
Previous Close	17.90
Day's Range	16.88 - 17.88
52-Week Range	9.31 - 19.64
Beta	n/a
RSI	46.15
Earnings Date	Apr 16, 2026

About Cinclus Pharma Holding AB

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CINPHA

Financial Performance

In 2025, Cinclus Pharma Holding AB's revenue was 57.47 million, an increase of 1154.80% compared to the previous year's 4.58 million. Losses were -183.97 million, 9.49% more than in 2024.